Literature DB >> 11553262

Analysis of the stem cell sparing properties of cyclophosphamide.

R V Gardner1, E McKinnon, C M Astle.   

Abstract

OBJECTIVES: Cyclophosphamide was examined for its ability to spare the most primitive hematopoietic stem cell (PHSC).
METHODS: C57BL6/J mice (Groups A and B) were sacrificed 24 h and 4-6 wk, respectively, after a single or second injection of low-dose cyclophosphamide (90 mg/kg) on days 1, 3, 7, or 15. A competitive repopulation assay was then performed, using B6-HbbdGpi-1a competitor cells, to determine the repopulating ability of exposed PHSC. RESULTS AND
CONCLUSIONS: PHSC function was preserved after a single injection of cyclophosphamide and after a second injection on days 7 and 15 in both groups. In Group A, PHSC repopulating ability declined after a second injection on days 1 and 3 (p<0.05 only for day 1), as did repopulating units [RU]; PHSC numbers did not. In Group B, an insignificant decrease in repopulating ability and RU numbers was observed after a second injection on days 1 and 3, suggesting different etiologies for losses in the 2 groups, or correction of drug-induced defects within 1 month of cyclophosphamide administration. Total RU increased in single, day 1, 7 and 15 treatment groups. A significant number of marrow cells entered the S phase after cyclophosphamide dosing on day 3, and it is possible that a relationship exists between cell cycling and replicative damage. DNA damage was also increased 1 and 3 d after cyclophosphamide administration, although the significance of differences from controls was not definitive.
CONCLUSION: Low-dose cyclophosphamide can spare stem cells, depending upon the timing of subsequent doses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553262     DOI: 10.1034/j.1600-0609.2001.067001014.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

Review 1.  Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches.

Authors:  Ann P Chidgey; Natalie Seach; Jarrod Dudakov; Maree V Hammett; Richard L Boyd
Journal:  Semin Immunopathol       Date:  2008-11-04       Impact factor: 9.623

Review 2.  Greater than the sum of their parts: combination strategies for immune regeneration following allogeneic hematopoietic stem cell transplantation.

Authors:  Jarrod A Dudakov; Marcel R M van den Brink
Journal:  Best Pract Res Clin Haematol       Date:  2011-06-29       Impact factor: 3.020

3.  Serial transplantation reveals a critical role for endoglin in hematopoietic stem cell quiescence.

Authors:  Luciene Borges; Vanessa K P Oliveira; June Baik; Sean C Bendall; Rita C R Perlingeiro
Journal:  Blood       Date:  2018-12-28       Impact factor: 22.113

4.  A novel assay to trace proliferation history in vivo reveals that enhanced divisional kinetics accompany loss of hematopoietic stem cell self-renewal.

Authors:  Jens M Nygren; David Bryder
Journal:  PLoS One       Date:  2008-11-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.